Patents by Inventor Deepa MEHTA

Deepa MEHTA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION AND METHOD FOR TREATING ARTHRITIS
    Publication number: 20260053770
    Abstract: The present invention discloses a composition and method for treating arthritis. The composition comprises a binary blend of molecules including citral, methyl cinnamate, and epicurzerenone. The binary blend exhibits synergistic efficacy in modulating inflammatory cytokines. The citral, methyl cinnamate, and epicurzerenone, are derived from essential oils of Cymbopogon citratus, Hedychium spicatum, and Zanthoxylum armatum, respectively. Both individual and binary blend exhibits downregulation of pro-inflammatory cytokines IL-2, IL-6, and TNF-?, and upregulation of anti-inflammatory cytokine IL-10.
    Type: Application
    Filed: August 23, 2024
    Publication date: February 26, 2026
    Applicant: Bordoloi Biotech LLC
    Inventors: Binoy K. Bordoloi, Ronen K. Bordoloi, Nicole Heeney, Deepa Mehta, KULWANT SINGH SAINI, Debojit Saikia, Sachin Kumar
  • IPTG-free induction process for expression of biosimilar rHu Ranibizumab antibody fragment using
    Patent number: 11578122
    Abstract: The present invention provides an improved process for inducing the expression of the light chain and heavy chain of the said rHu biosimilar Ranibizumab by employing natural sugars such as lactose and galactose. The replacement of IPTG with natural sugars overcomes the regulatory limitation of synthetic element trace contamination in the final drug substance and reduces the burden on the recombinant host cell.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: February 14, 2023
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Rahul Sharad Bhambure, Aatir Asad Tungekar, Deepa Mehta
  • IPTG-FREE INDUCTION PROCESS FOR EXPRESSION OF BIOSIMILAR RHU RANIBIZUMAB ANTIBODY FRAGMENT USING E. COLI
    Publication number: 20200165332
    Abstract: The present invention provides an improved process for inducing the expression of the light chain and heavy chain of the said rHu biosimilar Ranibizumab by employing natural sugars such as lactose and galactose. The replacement of IPTG with natural sugars overcomes the regulatory limitation of synthetic element trace contamination in the final drug substance and reduces the burden on the recombinant host cell.
    Type: Application
    Filed: January 29, 2020
    Publication date: May 28, 2020
    Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Rahul Sharad BHAMBURE, Aatir Asad TUNGEKAR, Deepa MEHTA